AbbVie Gets EC Approval of Rinvoq for Adults With Rheumatoid Arthritis
December 18 2019 - 11:37AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. (ABBV) on Wednesday said the European Commission
approved Rinvoq for the treatment of adults with moderate to severe
active rheumatoid arthritis who have responded inadequately to, or
who are intolerant to, one or more disease-modifying anti-rheumatic
drugs.
The North Chicago, Ill., biopharmaceutical company said Rinvoq
may be used as monotherapy or in combination with methotrexate.
AbbVie said the EC approval was supported by data from a global
phase 3 program in which Rinvoq met all primary and ranked
secondary endpoints across a variety of adult populations.
The U.S. Food and Drug Administration earlier this year approved
the drug for adults with moderately to severely active rheumatoid
arthritis who have had an inadequate response or intolerance to
methotrexate.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 18, 2019 11:22 ET (16:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024